BACKGROUND: Rapid diagnostic tests (RDTs) play a key role in malaria case management. The most widely used RDT identifies Plasmodium falciparum based on immunochromatographic recognition of P. falciparum histidine-rich protein 2 (PfHRP2). Deletion of the paralogous pfhrp2 and pfhrp3 genes leads to false-negative PfHRP2-based RDTs, and has been reported in P. falciparum infections from South America and Africa. However, identification of pfhrp2/pfhrp3 deletions has usually been based only on failure to amplify these genes using PCR, without confirmation based on PfHRP2 protein expression, and understanding of the true prevalence of deletions is incomplete. METHODS: Deletions of pfhrp2/pfhrp3 in blood samples were investigated from cross-sectional surveys in 2012-13 in three regions of varied malaria transmission intensity in Uganda. Samples with positive Giemsa-stained thick blood smears, but negative PfHRP2-based RDTs were evaluated by PCR amplification of conserved subunit ribosomal DNA for Plasmodium species, PCR amplification of pfhrp2 and pfhrp3 genes to identify deletions, and bead-based immunoassays for expression of PfHRP2. RESULTS: Of 3516 samples collected in cross-sectional surveys, 1493 (42.5%) had positive blood smears, of which 96 (6.4%) were RDT-negative. Of these 96 RDT-negative samples, P. falciparum DNA was identified by PCR in 56 (58%) and only non-falciparum plasmodial DNA in 40 (42%). In all 56 P. falciparum-positive samples there was a failure to amplify pfhrp2 or pfhrp3: in 25 (45%) pfhrp2 was not amplified, in 39 (70%) pfhrp3 was not amplified, and in 19 (34%) neither gene was amplified. For the 39 P. falciparum-positive, RDT-negative samples available for analysis of protein expression, PfHRP2 was not identified by immunoassay in only four samples (10.3%); these four samples all had failure to amplify both pfhrp2 and pfhrp3 by PCR. Thus, only four of 96 (4.2%) smear-positive, RDT-negative samples had P. falciparum infections with deletion of pfhrp2 and pfhrp3 confirmed by failure to amplify the genes by PCR and lack of expression of PfHRP2 demonstrated by immunoassay. CONCLUSION: False negative RDTs were uncommon. Deletions in pfhrp2 and pfhrp3 explained some of these false negatives, but most false negatives were not due to deletion of the pfhrp2 and pfhrp3 genes.
BACKGROUND: Rapid diagnostic tests (RDTs) play a key role in malaria case management. The most widely used RDT identifies Plasmodium falciparum based on immunochromatographic recognition of P. falciparum histidine-rich protein 2 (PfHRP2). Deletion of the paralogous pfhrp2 and pfhrp3 genes leads to false-negative PfHRP2-based RDTs, and has been reported in P. falciparum infections from South America and Africa. However, identification of pfhrp2/pfhrp3 deletions has usually been based only on failure to amplify these genes using PCR, without confirmation based on PfHRP2 protein expression, and understanding of the true prevalence of deletions is incomplete. METHODS: Deletions of pfhrp2/pfhrp3 in blood samples were investigated from cross-sectional surveys in 2012-13 in three regions of varied malaria transmission intensity in Uganda. Samples with positive Giemsa-stained thick blood smears, but negative PfHRP2-based RDTs were evaluated by PCR amplification of conserved subunit ribosomal DNA for Plasmodium species, PCR amplification of pfhrp2 and pfhrp3 genes to identify deletions, and bead-based immunoassays for expression of PfHRP2. RESULTS: Of 3516 samples collected in cross-sectional surveys, 1493 (42.5%) had positive blood smears, of which 96 (6.4%) were RDT-negative. Of these 96 RDT-negative samples, P. falciparum DNA was identified by PCR in 56 (58%) and only non-falciparum plasmodial DNA in 40 (42%). In all 56 P. falciparum-positive samples there was a failure to amplify pfhrp2 or pfhrp3: in 25 (45%) pfhrp2 was not amplified, in 39 (70%) pfhrp3 was not amplified, and in 19 (34%) neither gene was amplified. For the 39 P. falciparum-positive, RDT-negative samples available for analysis of protein expression, PfHRP2 was not identified by immunoassay in only four samples (10.3%); these four samples all had failure to amplify both pfhrp2 and pfhrp3 by PCR. Thus, only four of 96 (4.2%) smear-positive, RDT-negative samples had P. falciparum infections with deletion of pfhrp2 and pfhrp3 confirmed by failure to amplify the genes by PCR and lack of expression of PfHRP2 demonstrated by immunoassay. CONCLUSION: False negative RDTs were uncommon. Deletions in pfhrp2 and pfhrp3 explained some of these false negatives, but most false negatives were not due to deletion of the pfhrp2 and pfhrp3 genes.
Authors: Adithya Cattamanchi; Daniel Kyabayinze; Alan Hubbard; Philip J Rosenthal; Grant Dorsey Journal: Am J Trop Med Hyg Date: 2003-02 Impact factor: 2.345
Authors: Jonathan B Parr; Robert Verity; Stephanie M Doctor; Mark Janko; Kelly Carey-Ewend; Breanna J Turman; Corinna Keeler; Hannah C Slater; Amy N Whitesell; Kashamuka Mwandagalirwa; Azra C Ghani; Joris L Likwela; Antoinette K Tshefu; Michael Emch; Jonathan J Juliano; Steven R Meshnick Journal: J Infect Dis Date: 2017-07-01 Impact factor: 5.226
Authors: Avinash N Mukkala; Jason Kwan; Rachel Lau; David Harris; Dylan Kain; Andrea K Boggild Journal: Curr Infect Dis Rep Date: 2018-10-23 Impact factor: 3.725
Authors: Joseph F Abdallah; Sheila Akinyi Okoth; Gustavo A Fontecha; Rosa Elena Mejia Torres; Engels I Banegas; María Luisa Matute; Sandra Tamara Mancero Bucheli; Ira F Goldman; Alexandre Macedo de Oliveira; John W Barnwell; Venkatachalam Udhayakumar Journal: Malar J Date: 2015-01-21 Impact factor: 2.979
Authors: Agaba Katureebe; Kate Zinszer; Emmanuel Arinaitwe; John Rek; Elijah Kakande; Katia Charland; Ruth Kigozi; Maxwell Kilama; Joaniter Nankabirwa; Adoke Yeka; Henry Mawejje; Arthur Mpimbaza; Henry Katamba; Martin J Donnelly; Philip J Rosenthal; Chris Drakeley; Steve W Lindsay; Sarah G Staedke; David L Smith; Bryan Greenhouse; Moses R Kamya; Grant Dorsey Journal: PLoS Med Date: 2016-11-08 Impact factor: 11.069
Authors: Oliver J Watson; Hannah C Slater; Robert Verity; Jonathan B Parr; Melchior K Mwandagalirwa; Antoinette Tshefu; Steven R Meshnick; Azra C Ghani Journal: Elife Date: 2017-08-24 Impact factor: 8.140
Authors: Eric Rogier; Lotus van den Hoogen; Camelia Herman; Kevin Gurrala; Vena Joseph; Gillian Stresman; Jacquelin Presume; Ithamare Romilus; Gina Mondelus; Tamara Elisme; Ruth Ashton; Michelle Chang; Jean F Lemoine; Thomas Druetz; Thomas P Eisele; Alexandre Existe; Jacques Boncy; Chris Drakeley; Venkatachalam Udhayakumar Journal: Malar J Date: 2019-12-04 Impact factor: 2.979
Authors: Steven A Harvey; Larissa Jennings; Masela Chinyama; Fred Masaninga; Kurt Mulholland; David R Bell Journal: Malar J Date: 2008-08-22 Impact factor: 2.979
Authors: Beatus M Lyimo; Zachary R Popkin-Hall; David J Giesbrecht; Celine I Mandara; Rashid A Madebe; Catherine Bakari; Dativa Pereus; Misago D Seth; Ramadhan M Ngamba; Ruth B Mbwambo; Bronwyn MacInnis; Daniel Mbwambo; Issa Garimo; Frank Chacky; Sijenunu Aaron; Abdallah Lusasi; Fabrizio Molteni; Ritha Njau; Jane A Cunningham; Samwel Lazaro; Ally Mohamed; Jonathan J Juliano; Jeffrey A Bailey; Deus S Ishengoma Journal: Front Cell Infect Microbiol Date: 2022-07-13 Impact factor: 6.073